Detection of survivin 2α gene expression in thyroid nodules

Journal of Cancer Research and Therapeutics

Volumn 10, Issue 2, 2014, Pages 312-316

  Kyani, Keyhaneh ^a   Babaei, Esmaeil ^b   Feizi, Mohammad ^b   Vandghanooni, Somayeh ^c   Montazeri, Vahid ^d   Halimi, Monireh ^d  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b UNIVERSITY OF TABRIZ   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hemi Nested RT PCR; splice variant; survivin 2 ; thyroid cancer

Indexed keywords

BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; ISOPROTEIN; TUMOR MARKER;

FEMALE; GENE EXPRESSION; GENETICS; HUMAN; MALE; METABOLISM; THYROID NODULE;

FEMALE; GENE EXPRESSION; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; PROTEIN ISOFORMS; THYROID NODULE; TUMOR MARKERS, BIOLOGICAL;

EID: 84905693245     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.136598     Document Type: Article

References (23)

1. Franceschi S and Vecchia CL."Cancer of the thyroid," in Trends in Cancer Incidence and Mortality. Cold Spring Harbor Press, Cold Spring Harbor, NY, USA; 1994;19. p. 393-424.
2. Franceschi S, Preston-Martin S, Dal Maso L, Negri E, La Vecchia C, Mack WJ, et al. A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid disease. Cancer Causes Control 1999;10:583-95.
3. Parkin DM, Muir CS, Whelan SL, Gao YT, Ferlay J. Cancer incidence in five continents. Lyon: IARC Scientific Publications; 1992. p. 146-7.
4. Mulla ZD, Margo CE. Primary malignancies of the thyroid: Epidemiological analysis of the Florida cancer data system registry. Ann Epidemiol 2000;10:24-30.
5. Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999;96:245-54.
6. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis 2000;21:485-95
7. Nachmias B, Ashhab Y, Ben-Yehuda D. The inhibitor of apoptosis protein family (IAPs): An emerging therapeutic target in cancer. Semin Cancer Biol 2004;14:231-43.
8. Mazzanti C, Zeiger MA, Costourous N, Umbricht C, Westra WH, Smith D, et al. Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res 2004;64:2898-903.
9. Pavlidou A, Dalamaga M, Christos K, Konstantoudakis G, Belimezi M, Athanasas G, et al. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR. World J Gastroenterol 2011;17:1614-21.
10. Caldas H, Fangusaro JR, Boué DR, Holloway MP, Altura RA. Dissecting the role of endothelial survivin Ex3 in angiogenesis. Blood 2007;109:1479-89.
11. Li F. Role of survivin and its splice variants in tumorogenesis. Br J Cancer 2005;92:212-6.
12. Knauer KS, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rodel F, et al. The survivin isoform of survivin-3B is cytoprotective and can function as a chromosomal passanger complex protein. Cell Cycle 2007;12:1502-9.
13. Duffy JM, ÒDonovan N, Brennan JD, Gallagher MW, Ryan MB. Survivin: A promising tumor biomarker. Cancer Lett 2007;249:49-60.
14. Ouhtit A, Matrougui K, Bengrine A, KoocheK.P.our S, Zerfaoui M, Yousefi Z. Survivin is not only a death encounter but also a survival protein for invaliding tumor cells. Front Biosci 2007;12:1260-70.
15. Mahotka C, Wenzel M, Springer E, GabbertHE, Gerharz CD. Survivin-?Ex3 and survivin-2B: Two novel splice variants of the apoptosis inhibitor with different antiapoptotic properties. Cancer Res 1999;59:6097-102.
16. Caldas H, Honsey LE, Altura RA. Survivin 2?: A novel survivin splice variant expressed in human malignancies. Mol Cancer 2005;4:11.
17. Ryan B, ÒDonovan N, Browne B, O'Shea C, Crown J, Hill AD, et al. Expression of Survivin and its aplice variants Survivin 2B and Survivin-?Ex3 in breast cancer. Br J Cancer 2005;92:120-4.
18. Vandghanooni S, Eskandani M, Montazeri V, Halimi M, Babaei E, Hosseinpour Feizi MA. Survivin-deltaEx3: A novel biomarker for diagnosis of papillary thyroid carcinoma. J Cancer Res Ther 2011; 3: 332-337.
19. Solcia E, Klöppel G, Sobin LH. Histological Typing of Endocrine Tumours. WHO. World Health Organization. International Histological Classification of Tumours. 2nd ed. Springer; 2000.
20. Hu H, Shikama Y, Matsuoka I, Kimura J. Terminally differentiate neutrophils predominantly express Survivin 2?, a dominant-negative isoform of Survivin. J Leukoc Biol 2008;83:393-400.
21. Cheng Z, Hu L, Fu W, Zhang Q, Liao X. Expression of Survivin and Its Splice Variants in Gastric Cancer. J Huazhong Univ Sci Technolog Med Sci 2007;27:393-8.
22. Koike H, Sekin Y, Kamiya M, Nakazato H, Suzuki K. Gen expressiona of Survivin and its spliced isoform associated with proliferation and aggressive of prostate cancer aggressive phenotypes of prostate cancer. Urology 2008;72:1229-33.
23. Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos F, Marousi S, et al. The survivin ? 31 snp in human colorectal cancer correlates with Survivin splice variant expression and improved overall survival. Anal Cell Pathol (Amst) 2010;33:177-89.